Telomeric repeat-containing RNA is dysregulated in acute myeloid leukemia
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER
Autores
CATTO, Luiz Fernando B.
ZANELATTO, Leonardo C.
DONAIRES, Flavia S.
CARVALHO, Vinicius S. de
SANTANA, Barbara A.
PINTO, Andre L.
FANTACINI, Daianne
SOUZA, Lucas Eduardo B. de
FONSECA, Natasha P.
TELHO, Bruno S.
Citação
BLOOD ADVANCES, v.7, n.22, p.7067-7078, 2023
Resumo
TERRA (telomeric repeat-containing RNA) is a class of long noncoding RNAs transcribed from subtelomeric and telomeric regions. TERRA binds to the subtelomeric and telomeric DNA-forming R-loops (DNA-RNA hybrids), which are involved in telomere maintenance and telomerase function, but the role of TERRA in human cells is not well characterized. Here, we comprehensively investigated for the first time TERRA expression in primary human hematopoietic cells from an exploratory cohort of patients with acute myeloid leukemia (AML), patients with acute lymphoblastic leukemia (ALL), patients with telomere biology disorder (TBD), and healthy subjects. TERRA expression was repressed in primary human hematopoietic cells, including healthy donors, patients with ALL, and patients with TBD, irrespective of their telomere length, except for AML. A second cohort comprising 88 patients with AML showed that TERRA was overexpressed in an AML subgroup also characterized by higher R-loop formation, low TERT and RNAseH2 expression, and a paucity of somatic splicing factor mutations. Telomere length did not correlate with TERRA expression levels. To assess the role of TERRA R-loops in AML, we induced R-loop depletion by increasing RNAseH1 expression in 2 AML cell lines. Decreased TERRA R-loops in AML cell lines resulted in increased chemosensitivity to cytarabine. Our findings indicate that TERRA is uniformly repressed in primary human hematopoietic cells but abnormally expressed in an AML subset with low telomerase.
Palavras-chave
Referências
- Arora R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6220
- Azzalin CM, 2007, SCIENCE, V318, P798, DOI 10.1126/science.1147182
- Calado RT, 2009, NEW ENGL J MED, V361, P2353, DOI 10.1056/NEJMra0903373
- Campo E., 2017, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
- Chen L, 2018, MOL CELL, V69, P412, DOI 10.1016/j.molcel.2017.12.029
- Chu HP, 2017, CELL, V170, P86, DOI 10.1016/j.cell.2017.06.017
- Cusanelli E, 2013, MOL CELL, V51, P780, DOI 10.1016/j.molcel.2013.08.029
- Douer D, 1996, BLOOD, V87, P308, DOI 10.1182/blood.V87.1.308.bloodjournal871308
- Episkopou H, 2014, NUCLEIC ACIDS RES, V42, P4391, DOI 10.1093/nar/gku114
- Farnung BO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035714
- Feretzaki M, 2019, RNA, V25, P1470, DOI 10.1261/rna.072322.119
- Feretzaki M, 2017, METHODS, V114, P39, DOI 10.1016/j.ymeth.2016.08.004
- Fernandes RV, 2023, NUCLEIC ACIDS RES, V51, P6702, DOI 10.1093/nar/gkad448
- Fernandes RV, 2021, CELL CYCLE, V20, P1745, DOI 10.1080/15384101.2021.1962638
- Gallardo F, 2011, MOL CELL, V44, P819, DOI 10.1016/j.molcel.2011.09.020
- García-Muse T, 2019, CELL, V179, P604, DOI 10.1016/j.cell.2019.08.055
- Goldberg AD, 2010, CELL, V140, P678, DOI 10.1016/j.cell.2010.01.003
- Graf M, 2017, CELL, V170, P72, DOI 10.1016/j.cell.2017.06.006
- Gutierrez-Rodrigues F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113747
- Heuser M, 2021, BLOOD, V138, P2753, DOI 10.1182/blood.2021013626
- Kreilmeier T, 2016, GENES-BASEL, V7, DOI 10.3390/genes7080046
- Kroupa M, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.913314
- de Silanes IL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5723
- Maciejowski J, 2017, NAT REV MOL CELL BIO, V18, P175, DOI 10.1038/nrm.2016.171
- Marani LO, 2021, Hematol Transfus Cell Ther, V43, pS183
- Mei Y, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82406-x
- Metsalu T, 2015, NUCLEIC ACIDS RES, V43, pW566, DOI 10.1093/nar/gkv468
- Misino S, 2018, DIFFERENTIATION, V100, P37, DOI 10.1016/j.diff.2018.02.002
- Moravec M, 2016, EMBO REP, V17, P999, DOI 10.15252/embr.201541708
- MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
- MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622
- Nguyen DH, 2021, BLOOD, V138, DOI 10.1182/blood-2021-149688
- Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350
- Pfeiffer V, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002747
- Porro A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6379
- Redon S, 2010, NUCLEIC ACIDS RES, V38, P5797, DOI 10.1093/nar/gkq296
- Rego EM, 2011, MEDITERR J HEMATOL I, V3, DOI [10.4084/mjhid.2011.049, 10.4084/MJHID.2011.049]
- Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
- Sagie S, 2014, HUM MOL GENET, V23, P3629, DOI 10.1093/hmg/ddu071
- Schoeftner S, 2008, NAT CELL BIOL, V10, P228, DOI 10.1038/ncb1685
- Schuurhuis GJ, 2018, BLOOD, V131, P1275, DOI 10.1182/blood-2017-09-801498
- Shay JW, 2000, NAT REV MOL CELL BIO, V1, P72, DOI 10.1038/35036093
- Silva B, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24097-6
- Smekalova E, 2013, MOL CELL, V51, P703, DOI 10.1016/j.molcel.2013.09.011
- SZOSTAK JW, 1982, CELL, V29, P245, DOI 10.1016/0092-8674(82)90109-X
- Toubiana S, 2020, CURR OPIN GENET DEV, V60, P9, DOI 10.1016/j.gde.2020.02.004
- von Morgen P, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0596-4
- Wang CQ, 2015, INT J BIOL SCI, V11, P316, DOI 10.7150/ijbs.10528
- Weemaes CMR, 2013, EUR J HUM GENET, V21, P1219, DOI 10.1038/ejhg.2013.40
- Wells JP, 2019, TRENDS CANCER, V5, P619, DOI 10.1016/j.trecan.2019.08.006
- Yehezkel S, 2008, HUM MOL GENET, V17, P2776, DOI 10.1093/hmg/ddn177
- Yehezkel S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00035
- Yu TY, 2014, P NATL ACAD SCI USA, V111, P3377, DOI 10.1073/pnas.1307415111
- Zhong L, 2015, MOL DIAGN THER, V19, P205, DOI 10.1007/s40291-015-0147-2